Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Benchmarking of mutation diagnostics in clinical lung cancer specimens.

PloS one - 5 May 2011

Querings Silvia, Altmüller Janine, Ansén Sascha, Zander Thomas, Seidel Danila, Gabler Franziska, Peifer Martin, Markert Eva, Stemshorn Kathryn, Timmermann Bernd, Saal Beate, Klose Stefan, Ernestus Karen, Scheffler Matthias, Engel-Riedel Walburga, Stoelben Erich, Brambilla Elisabeth, Wolf Jürgen, Nürnberg Peter, Thomas Roman K

Abstract excerpt

Treatment of EGFR-mutant non-small cell lung cancer patients with the tyrosine kinase inhibitors erlotinib or gefitinib results in high response rates and prolonged progression-free survival. Despite the development of sensitive mutation detection approaches, a thorough validation of these in a c...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benchmarking
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to ErbB Receptors

Share to Genome, Human

Share to Lung Neoplasms

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 21573178
DOI: 10.1371/journal.pone.0019601
PMCID: PMC3088700

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21573178-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Benchmarking of mutation diagnostics in clinical lung cancer specimens.PMID 21573178Read ↗

Pyrosequencing for EGFR mutation detection: diagnostic accuracy and clinical implications.Semantic proximity Read ↗

Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing.Semantic proximity Read ↗

Utility of different massive parallel sequencing platforms for mutation profiling in clinical samples and identification of pitfalls using FFPE tissue.Semantic proximity Read ↗

Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer.Semantic proximity Read ↗

Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing.Semantic proximity Read ↗

Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC.Semantic proximity Read ↗

Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer.Semantic proximity Read ↗

Not enough can be enough: feasibility of the Idylla EGFR mutation test when reuse of stained tissue slides is the only option available.Semantic proximity Read ↗

Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation.Semantic proximity Read ↗

High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas.Semantic proximity Read ↗

High degree of polyclonality hinders somatic mutation calling in lung brush samples of COPD cases and controls.Semantic proximity Read ↗

Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.